GlycoMimetics Shares Are Soaring Tuesday: Here's Why
GlycoMimetics Shares Are Soaring Tuesday: Here's Why
The merger transaction is anticipated to close in the second quarter of 2025, with the financing transaction expected to close immediately afterward.GlycoMimetics, Inc. (NASDAQ:GLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent Biopharma. The company also said it secured $200 million in funding to advance its oncology pipeline.
納斯達克的GlycoMimetics股票週二上漲，因爲該公司宣佈將與Crescent Biopharma合併。該公司還表示已獲得20000萬美元的資金，以推進其腫瘤藥物管線。
What To Know: GlycoMimetics has entered into an acquisition agreement with privately held biotech firm Crescent BioPharma. The combined company, which will operate under the name Crescent Biopharma, Inc., will focus on advancing Crescent Biopharma's current solid tumor portfolio, including its lead therapies CR-001, CR-002 and CR-003.
了解一下：GlycoMimetics已與私人生物技術公司Crescent BioPharma簽訂了收購協議。合併後的公司將以Crescent Biopharma, Inc.的名義運營，重點是推進Crescent Biopharma當前的實體瘤產品組合，包括其主導療法CR-001、CR-002和CR-003。
In support of the merger, a group of investors has agreed to purchase $200 million in the combined company's common stock and pre-funded warrants. The purpose of the funding is to support operations through 2027, including further developing lead therapeutic treatments.
爲支持合併，一群投資者已同意購買合併公司普通股和預融資認股權20000萬美元。此次資金注入的目的是支持截至2027年的運營，包括進一步發展主導治療方案。
The merger transaction is anticipated to close in the second quarter of 2025, with the financing transaction expected to close immediately afterward.
預計合併交易將在2025年第二季度結束，融資交易預計隨即結束。
Under the acquisition agreement, pre-acquisition GlycoMimetics stockholders will hold about 3.1% of the combined company, while pre-acquisition Crescent stockholders, including those involved in pre-closing financing, will own roughly 96.9%.
根據收購協議，收購前的GlycoMimetics股東將持有合併公司約3.1%的股份，而包括參與封閉前融資的收購前Crescent股東將擁有約96.9%的股份。
"We are confident that our transaction with Crescent represents a significant opportunity for GlycoMimetics and its stockholders," said Harout Semerjian, CEO of GlycoMimetics.
「我們相信與Crescent的交易對GlycoMimetics及其股東來說是一個重要機會，」GlycoMimetics首席執行官Harout Semerjian說。
"This transaction is the result of a comprehensive strategic review, and with additional funding for Crescent's portfolio of novel biologics, we believe the company is well-positioned to carry forward the mission of seeking to improve the lives of patients."
「本次交易是經過全面戰略審查的結果，通過爲Crescent的新型生物製品組合提供額外資金，我們相信公司已經處於良好位置，繼續致力於提高患者的生活質量使命。」
GlycoMimetics stock is trading on above-average volume Tuesday. The company's average session volume over the past 100 days is 1.05 million, but Tuesday's trading volume was around 856 million at the time of publication.
週二，GlycoMimetics股票以高於平均水平的成交量交易。公司過去100天的平均成交量爲105萬，但本週二的交易量在發佈時約爲85600萬。
Related Link: What's Going On With Boeing Stock Monday?
相關鏈接：波音股票週一的最新動向是什麼？
GLYC Price Action: At the time of publication, GlycoMimetics shares are up 210.1% at 52 cents, according to data from Benzinga Pro.
GLYC價格走勢：根據Benzinga Pro提供的數據，在發佈時，GlycoMimetics股價上漲210.1%，達到52美分。
Image: Image: Akava Photo from Pixabay
圖片: 圖片: 來自Pixabay的Akava照片
